Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b

Elisabetta Vergani, Lorenza Di Guardo, Matteo Dugo, Sara Rigoletto, Gabrina Tragni, Roberta Ruggeri, Federica Perrone, Elena Tamborini, Annunziata Gloghini, Flavio Arienti, Barbara Vergani, Paola Deho, Loris De Cecco, Viviana Vallacchi, Paola Frati, Eriomina Shahaj, Antonello Villa, Mario Santinami, Filippo De Braud, Licia RivoltiniMonica Rodolfo

Research output: Contribution to journalArticle

Abstract

In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of cytokine production contributing to tumor progression and drug resistance. Among the factors produced by PLX4032-resistant melanoma cell lines, CCL2 was higher compared to the sensitive parental cell lines and increased upon drug treatment. CCL2 acted as an autocrine growth factor for melanoma cells, stimulating the proliferation and resistance to apoptosis. In patients, CCL2 is detected in melanoma cells in tumors and in plasma at levels that correlate with tumor burden and lactate dehydrogenase. Vemurafenib treatment increased the CCL2 levels in plasma, whereas the long-term clinical response was associated with low CCL2 levels. Increased CCL2 production was associated with miRNA deregulation in the resistant cells. miR-34a, miR-100 and miR-125b showed high expression in both resistant cells and in tumor biopsies that were obtained from treated patients, and they were involved in the control of cell proliferation and apoptosis. Inhibition of CCL2 and of the selected miRNAs restored both the cell apoptosis and the drug efficacy in resistant melanoma cells. Therefore, CCL2 and miRNAs are potential prognostic factors and attractive targets for counteracting treatment resistance in metastatic melanoma.

Original languageEnglish
Pages (from-to)4428-4441
Number of pages14
JournalOncotarget
Volume7
Issue number4
DOIs
Publication statusPublished - 2016

Fingerprint

Melanoma
MicroRNAs
Apoptosis
Cell Proliferation
Cell Line
Neoplasms
Tumor Burden
L-Lactate Dehydrogenase
Drug Resistance
Pharmaceutical Preparations
PLX4032
Intercellular Signaling Peptides and Proteins
Therapeutics
Cytokines
Biopsy

Keywords

  • BRAF inhibitor
  • CCL2
  • Drug resistance
  • Melanoma
  • MiRNAs

ASJC Scopus subject areas

  • Oncology

Cite this

Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. / Vergani, Elisabetta; Di Guardo, Lorenza; Dugo, Matteo; Rigoletto, Sara; Tragni, Gabrina; Ruggeri, Roberta; Perrone, Federica; Tamborini, Elena; Gloghini, Annunziata; Arienti, Flavio; Vergani, Barbara; Deho, Paola; De Cecco, Loris; Vallacchi, Viviana; Frati, Paola; Shahaj, Eriomina; Villa, Antonello; Santinami, Mario; De Braud, Filippo; Rivoltini, Licia; Rodolfo, Monica.

In: Oncotarget, Vol. 7, No. 4, 2016, p. 4428-4441.

Research output: Contribution to journalArticle

@article{d14f5d18dca84bfa8b348aebd82078be,
title = "Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b",
abstract = "In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of cytokine production contributing to tumor progression and drug resistance. Among the factors produced by PLX4032-resistant melanoma cell lines, CCL2 was higher compared to the sensitive parental cell lines and increased upon drug treatment. CCL2 acted as an autocrine growth factor for melanoma cells, stimulating the proliferation and resistance to apoptosis. In patients, CCL2 is detected in melanoma cells in tumors and in plasma at levels that correlate with tumor burden and lactate dehydrogenase. Vemurafenib treatment increased the CCL2 levels in plasma, whereas the long-term clinical response was associated with low CCL2 levels. Increased CCL2 production was associated with miRNA deregulation in the resistant cells. miR-34a, miR-100 and miR-125b showed high expression in both resistant cells and in tumor biopsies that were obtained from treated patients, and they were involved in the control of cell proliferation and apoptosis. Inhibition of CCL2 and of the selected miRNAs restored both the cell apoptosis and the drug efficacy in resistant melanoma cells. Therefore, CCL2 and miRNAs are potential prognostic factors and attractive targets for counteracting treatment resistance in metastatic melanoma.",
keywords = "BRAF inhibitor, CCL2, Drug resistance, Melanoma, MiRNAs",
author = "Elisabetta Vergani and {Di Guardo}, Lorenza and Matteo Dugo and Sara Rigoletto and Gabrina Tragni and Roberta Ruggeri and Federica Perrone and Elena Tamborini and Annunziata Gloghini and Flavio Arienti and Barbara Vergani and Paola Deho and {De Cecco}, Loris and Viviana Vallacchi and Paola Frati and Eriomina Shahaj and Antonello Villa and Mario Santinami and {De Braud}, Filippo and Licia Rivoltini and Monica Rodolfo",
year = "2016",
doi = "10.18632/oncotarget.6599",
language = "English",
volume = "7",
pages = "4428--4441",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "4",

}

TY - JOUR

T1 - Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b

AU - Vergani, Elisabetta

AU - Di Guardo, Lorenza

AU - Dugo, Matteo

AU - Rigoletto, Sara

AU - Tragni, Gabrina

AU - Ruggeri, Roberta

AU - Perrone, Federica

AU - Tamborini, Elena

AU - Gloghini, Annunziata

AU - Arienti, Flavio

AU - Vergani, Barbara

AU - Deho, Paola

AU - De Cecco, Loris

AU - Vallacchi, Viviana

AU - Frati, Paola

AU - Shahaj, Eriomina

AU - Villa, Antonello

AU - Santinami, Mario

AU - De Braud, Filippo

AU - Rivoltini, Licia

AU - Rodolfo, Monica

PY - 2016

Y1 - 2016

N2 - In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of cytokine production contributing to tumor progression and drug resistance. Among the factors produced by PLX4032-resistant melanoma cell lines, CCL2 was higher compared to the sensitive parental cell lines and increased upon drug treatment. CCL2 acted as an autocrine growth factor for melanoma cells, stimulating the proliferation and resistance to apoptosis. In patients, CCL2 is detected in melanoma cells in tumors and in plasma at levels that correlate with tumor burden and lactate dehydrogenase. Vemurafenib treatment increased the CCL2 levels in plasma, whereas the long-term clinical response was associated with low CCL2 levels. Increased CCL2 production was associated with miRNA deregulation in the resistant cells. miR-34a, miR-100 and miR-125b showed high expression in both resistant cells and in tumor biopsies that were obtained from treated patients, and they were involved in the control of cell proliferation and apoptosis. Inhibition of CCL2 and of the selected miRNAs restored both the cell apoptosis and the drug efficacy in resistant melanoma cells. Therefore, CCL2 and miRNAs are potential prognostic factors and attractive targets for counteracting treatment resistance in metastatic melanoma.

AB - In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of cytokine production contributing to tumor progression and drug resistance. Among the factors produced by PLX4032-resistant melanoma cell lines, CCL2 was higher compared to the sensitive parental cell lines and increased upon drug treatment. CCL2 acted as an autocrine growth factor for melanoma cells, stimulating the proliferation and resistance to apoptosis. In patients, CCL2 is detected in melanoma cells in tumors and in plasma at levels that correlate with tumor burden and lactate dehydrogenase. Vemurafenib treatment increased the CCL2 levels in plasma, whereas the long-term clinical response was associated with low CCL2 levels. Increased CCL2 production was associated with miRNA deregulation in the resistant cells. miR-34a, miR-100 and miR-125b showed high expression in both resistant cells and in tumor biopsies that were obtained from treated patients, and they were involved in the control of cell proliferation and apoptosis. Inhibition of CCL2 and of the selected miRNAs restored both the cell apoptosis and the drug efficacy in resistant melanoma cells. Therefore, CCL2 and miRNAs are potential prognostic factors and attractive targets for counteracting treatment resistance in metastatic melanoma.

KW - BRAF inhibitor

KW - CCL2

KW - Drug resistance

KW - Melanoma

KW - MiRNAs

UR - http://www.scopus.com/inward/record.url?scp=84958019881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958019881&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6599

DO - 10.18632/oncotarget.6599

M3 - Article

AN - SCOPUS:84958019881

VL - 7

SP - 4428

EP - 4441

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 4

ER -